Abbott Laboratories (ABT)vs20/20 Biolabs, Inc. Common Stock (AIDX)
ABT
Abbott Laboratories
$92.17
+1.59%
HEALTHCARE · Cap: $163.94B
AIDX
20/20 Biolabs, Inc. Common Stock
$0.61
-7.75%
HEALTHCARE · Cap: $6.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 2446585% more annual revenue ($45.13B vs $1.84M). ABT leads profitability with a 13.9% profit margin vs -279.1%. ABT earns a higher WallStSmart Score of 54/100 (C-).
ABT
Buy54
out of 100
Grade: C-
AIDX
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-32.7%
Fair Value
$70.91
Current Price
$92.17
$21.26 premium
Intrinsic value data unavailable for AIDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Earnings declined 19.7%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -354.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : AIDX
The strongest argument for AIDX centers on Debt/Equity, Price/Book.
Bear Case : ABT
The primary concerns for ABT are P/E Ratio, EPS Growth.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABT profiles as a value stock while AIDX is a turnaround play — different risk/reward profiles.
ABT carries more volatility with a beta of 0.62 — expect wider price swings.
ABT is growing revenue faster at 7.8% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Bottom Line
ABT scores higher overall (54/100 vs 21/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is an innovative biotechnology firm committed to revolutionizing genomic research and diagnostics through its advanced laboratory services. With a keen focus on enhancing the accuracy and efficiency of genetic testing for clinical and research purposes, the company is poised to be a leader in the molecular diagnostics landscape. By leveraging state-of-the-art technologies, 20/20 Biolabs is strategically positioned to capitalize on the growing demand for personalized medicine and genomic data. Its strong market presence and forward-thinking initiatives underscore a compelling growth outlook within the rapidly evolving biotechnology sector.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?